INTRA-CAVITY RONKOLEUKIN IMMUNOTHERAPY IN TREATMENT RESISTANT PATIENTS WITH MALIGNANT EFFUSIONS
- Authors: Tltov K.1, Klselevsky M.2, Shublna I.2, Izrallov R.1, Semenov N.1
-
Affiliations:
- Moscow Clinical Research Centre
- N.N. Blokhin Russian Cancer Research Centre
- Issue: Vol 26, No 11 (2015)
- Pages: 52-55
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/116432
- ID: 116432
Cite item
Abstract
Keywords
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
K. Tltov
Moscow Clinical Research Centre
Email: ks-titov@mail.ru
Candidate of Medical Sciences
M. Klselevsky
N.N. Blokhin Russian Cancer Research CentreProfessor
I. Shublna
N.N. Blokhin Russian Cancer Research CentreDoctor of Biological Sciences
R. Izrallov
Moscow Clinical Research CentreProfessor
N. Semenov
Moscow Clinical Research Centre
References
- Сельчук В.Ю., Бычков М.Б., Киселевский М.Б. Опухолевые серозиты / М.: Практическая медицина, 2011; с. 278.
- Титов К.С., Демидов Л.В, Шубина И.Ж. и др. Сравнение эффективности и переносимости внутрибрюшинной клеточной и ИЛ-2-иммунотерапии у больных с химиорезистентными асцитными формами рака желудка // Рос. онкол. журн. - 2014; 3: 24-8.
- Киселевский М.В. Адоптивная иммунотерапия при злокачественных опухолях // Вестник РАМН. - 2003; 1: 40-4.
- Xue S., Stauss H. Enhancing immune responses for cancer therapy // Cell Mol. Immunol. - 2007; 4 (3): 173-84.
- Manjili M. Revisiting cancer immunoediting by understanding cancer immune complexity // J. Pathol. - 2011; 224 (1): 5-9.
- Wang E., Panelli M., Monsurrô V. et al. A global approach to tumor immunology // Cell Mol. Immunol. - 2004; 1 (4): 256-65.
- Sutlu T., Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects // J. Intern. Med. - 2009; 1: 154-81.
- June C. Adoptive T cell therapy for cancer in the clinic // J. Clin. Invest. -2007; 117 (6): 1466-76.
- Rosenberg S., Lotze M., Yang J. et al. Prospective randomized trial of highdose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer // J. Natl. Cancer Inst. - 1993; 85 (8): 622-32.
- Hontscha C., Borck Y., Zhou H. et al. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC) // J. Cancer Res. Clin. Oncol. -2011; 137 (2): 305-10.
- Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors // J. Cancer. - 2011; 2: 363-8.
- Liu X., Li D., Zhang C. et al. Treatment of 121 patients with malignant effusion due to advanced lung cancer by intrapleural transfer of autologous or allogeneic LAK cells combined with rIL-2 // Chin. Med. Sci. J. - 1993; 8(3): 186-9.
- Ruggeri L., Capanni M., Urbani E. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants // Science. - 2002; 295: 2097-100.
Supplementary files
![](/img/style/loading.gif)